Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.60 |
| ▸ | QPCT | Q16769 | 1/20 | 0.50 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7414532 | 0.87 | FGFR1 (0.59) | HTTFGFR1 | |
| SCHEMBL18696058 | 0.84 | KDR (0.55) | HTTFGFR1 | |
| SCHEMBL1408316 | 0.83 | FGFR1 (0.66) | HTTFGFR1 | |
| SCHEMBL17315054 | 0.83 | KDR (0.54) | HTTFGFR1 | |
| Bicarbonate SCHEMBL2334509 | 0.82 | HTT (0.85) | HTTFGFR1 | |
| SCHEMBL1408250 | 0.82 | FGFR1 (0.62) | HTTFGFR1QPCT | |
| SCHEMBL12970574 | 0.81 | FGFR1 (0.68) | HTTFGFR1 | |
| SCHEMBL29776603 | 0.81 | SIK1 (0.52) | FGFR1QPCT | |
| SCHEMBL28577316 | 0.81 | SIK1 (0.52) | FGFR1QPCT | |
| SCHEMBL30402227 | 0.80 | HTT (0.88) | HTTFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120184561-A1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-07-19 | — | — | US | disclosed |
| US-8030311-B2 | Phenylacetamides suitable as protein kinase inhibitors | NOVARTIS AG (CH) | 2011-10-04 | — | — | US | disclosed |
| US-7977338-B2 | Phenylacetamides being FLT3 inhibitors | NOVARTIS AG (CH) | 2011-07-12 | — | — | US | disclosed |
| EP-1874770-B1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-03-09 | — | — | EP | disclosed |
| US-20100075980-A1 | Phenylacetamides being FLT3 Inhibitors | NOVARTIS AG (CH) | 2010-03-25 | — | — | US | disclosed |
| EP-2074125-A1 | PHENYLACETAMIDES USEFUL AS PROTEIN KINASE INHIBITORS | Novartis Ag (CH) | 2009-07-01 | — | — | EP | disclosed |
| US-20080319005-A1 | Phenylacetamides Suitable as Protein Kinase Inhibitors | NOVARTIS AG (CH) | 2008-12-25 | — | — | US | disclosed |
| WO-2008046802-A1 | PHENYLACETAMIDES USEFUL AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-04-24 | — | — | WO | disclosed |
| EP-1874770-A1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | Novartis Pharma AG (CH) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006108640-A1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184561-A1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | MAP3K10, MAP3K20, MAP3K9 | HTT 2879/4885FGFR1 715/4885QPCT 1306/4885 |
| US-20100075980-A1 | Phenylacetamides being FLT3 Inhibitors | FLT3, JAK2, ABL1 | HTT 2043/4885FGFR1 87/4885QPCT 422/4885 |
| US-20080319005-A1 | Phenylacetamides Suitable as Protein Kinase Inhibitors | MAP3K20, MAP3K10, MAP3K9 | HTT 2940/4885FGFR1 670/4885QPCT 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.